It officially changed from concern over inflation and interest rates to fear of recession, which is causing a change in where traders position themselves.
The SPDR S&P Biotech ETF is one of the better-looking charts on this trader's screen, as is an individual biotech name.
The next six months can't be worse than the first six, can they?
Keep in mind that no matter how much a stock has fallen, it can always go lower, and it appears these four stocks could prove that point.
A key goal is to keep from losing money while the current bear runs its course, and don't count on positive seasonality leading to the Fourth of July.
It's possible, but unlikely, as we've yet to see the commodity complex hold gains forged in a bull market.
However, long-term investors would do well not to try to pick a bottom in the chipmaker's stock.
It wasn't a pretty day for most tech stocks, but it wasn't a disaster, either.
The maker of building products appears significantly undervalued based on its results and earnings prospects; here's how to play it.
This stock has been in the doghouse with investors for more than a year but has seen its shares turn higher of late.